The Obesity Race Has a Tariff Problem, and Amgen and Regeneron Aren't Exposed the Same Way
Washington's new pharma tariff-and-MFN framework rewards onshored manufacturing, and Amgen's early bet on domestic obesity-drug capacity puts it in a different position than Regeneron's more traditional, partner-heavy setup.
In April 2026, the White House proclaimed Section 232 tariffs on imported patented drugs and active pharmaceutical ingredients (APIs) — up to 100% ad valorem — with a carve-out: companies that sign Most Favored Nation (MFN) pricing deals with HHS and commit to onshoring get a 0% rate, at least until January 2029. That's not a symbolic gesture. It's a direct margin lever on exactly the drugs everyone wants exposure to right now: obesity therapeutics. And because biologics manufacturing is split into two distinct steps — API/drug-substance production (bioreactors, cell culture) versus fill-finish (formulation into injectable pens/vials) — the tariff bites differently depending on where each company actually makes the molecule, not just where it's headquartered.
Who cashes in
Discussion
No comments yet — start the conversation.
Money Racket Pro
By the time it's news, the money's already moved.
The contract award, the executive order, the tariff cut — it mints winners before the financial press connects the dots. Pro gets you there first: what happened, who cashes in, and exactly what to watch — in a two-minute read.
